4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

Four highly rated drugmakers beat analysts' second-quarter estimates Tuesday, but they generally followed this season's trend of guiding conservatively. Specialty/generics giant Actavis' (ACT) earnings rose 70% vs. a year earlier to $3.42 a share, beating forecasts by 5 cents. Sales rose 34% to $2.67 billion, more than $100 million above estimates. The company offered its first guidance since it ...

Technology is a subscriber feature. Take a free trial now to get instant access.

Try the Digital + Weekly Print Combo and enjoy the best of both worlds!eIBD is available after market close to give you a head start on the next day's market action. Plus, you get the Weekly Special print edition delivered right to your home or office!

Select market data is provided by Interactive Data Corp. Real Time Services. Price and Volume data is delayed 20 minutes unless otherwise noted, is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services terms. All times are Eastern United States. *Reflects real-time index prices.